Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Now available on-demand! Cracking the code: learnings from oligonucleotide method development WATCH NOW

Poster: Comparative metabolomics analysis of prostate cancer cells with different ethnic and tumorigenic phenotypes (Waters Corporation)

7 Oct 2014
General interest

A comprehensive high-throughput lipidomics and metabolomics analysis of prostate cancer cells with different tumorigenic phenotypes reveal potential markers for aggressive disease.

Click here to view poster

Related Links

  • Waters Corporation

Top content

  • Sanofi snaps up Dynavax in US $2.2B deal

Related tags

cancer high-throughput metabolomics
Previous article

Related articles

25 FEB 2016 CLINICAL
Imaging mass spectrometry clinical applications part I: examples from the literature
25 APR 2013 CLINICAL
How do cancer tumors develop resistance?
15 JAN 2013 COLLABORATIONS AND MERGERS
New partnership to explore cancer nanotherapeutics
21 OCT 2015 DRUG DEVELOPMENT
Press release: Bruker introduces the Molecular Drug Imager™ solution for small molecule drug discovery and development
26 MAY 2016 DATA PROCESSING AND INTERPRETATION
Zoltan Takats talks about Perfecting your image – mass spectrometry
CAR T-Cell therapy
20 SEP 2023 NEWS
Kite Pharma announces Phase II study results investigating the use of CAR T-cell therapy Yescarta®
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone